The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) can block cell death, new research has shown, making it a cancer drug target.
List view / Grid view
Enzymes are macromolecular biological catalysts. Enzymes accelerate, or catalyse, chemical reactions.
Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
Scientists have discovered that manipulating residues enables precision during the antibiotic biosynthesis assembly line.
Researchers have shown that miR-29 can control brain maturation in mammals, presenting a target for autism, epilepsy and other conditions.
Inhibiting the KDM4A enzyme slowed the growth of head and neck cancer in mouse models, also demonstrating promise to aid immunotherapy.
Researchers have shown that the PLpro coronavirus enzyme presents a possible target in the fight against COVID-19.
Using X-ray crystallography and simulations, researchers have shown that APT2 is a hybrid between a lipid carrier protein and a hydrolase.
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
A study has shown that inhibiting the enzyme PRMT5 can suppress the growth of glioblastoma cells in pre-clinical studies.
Researchers have discovered that all childhood neuroblastomas come from sympathoblasts, making them a drug target to treat the condition.
In a new study, inhibitors of the GLS1 enzyme caused the death of senescent cells and relieved the symptoms of various age-related diseases in mice.
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.